Form 4: BioCryst Legal Officer Sells Shares Under 10b5-1 Plan

BioCryst Pharmaceuticals' Chief Legal Officer, Alane P. Barnes, reported the sale of common stock and shares withheld for taxes, both executed under a pre-arranged 10b5-1 trading plan.

Summary

• Alane P. Barnes, Chief Legal Officer of BioCryst Pharmaceuticals Inc., reported two transactions involving common stock.
• On December 19, 2025, 16,902 shares were withheld by the issuer at a price of $7.41 per share to cover tax obligations related to the vesting of restricted stock units. This was not a discretionary sale by the reporting person.
• On December 22, 2025, 21,773 shares were sold at a price of $7.65 per share. This sale was executed automatically under a Rule 10b5-1 trading plan adopted on August 13, 2025.
• Following these transactions, Alane P. Barnes beneficially owns 398,751 shares of BioCryst common stock.

Sentiment

Score: 5

Explanation: Neutral. The filing reports routine insider transactions, including a sale and tax withholding, both executed under a pre-arranged 10b5-1 plan. This type of transaction is generally not indicative of a strong positive or negative sentiment regarding the company's immediate prospects.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating pre-planned, non-discretionary sales, which often mitigates concerns about opportunistic insider selling.

Negatives

• A net reduction in the Chief Legal Officer's direct beneficial ownership of common stock by 38,675 shares (16,902 shares withheld for taxes + 21,773 shares sold).

Future Outlook

N/A

Industry Context

This is a routine disclosure of insider stock transactions, common across all publicly traded companies, and does not inherently reflect specific industry trends for the biotechnology sector.

Related Party Transactions

• Alane P. Barnes, Chief Legal Officer, engaged in transactions involving company common stock, which are considered related party transactions due to her executive position.

Stakeholder Impact

• Shareholders: The net reduction in insider ownership, while pre-planned, could be viewed by some as a slight negative, though the 10b5-1 plan mitigates concerns of opportunistic selling. The overall impact is likely minimal given the routine nature of such disclosures.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions by the Chief Legal Officer, including a sale and tax-related withholding, both executed under a pre-established 10b5-1 plan. Such transactions are typically non-discretionary and do not provide new fundamental information about the company's operational performance or future prospects. Therefore, it does not warrant a change in investment recommendation based solely on this disclosure.

Keywords

BioCryst Pharmaceuticals, BCRX, Insider Trading, Form 4, Alane P. Barnes, Chief Legal Officer, Stock Sale, 10b5-1 Plan, Restricted Stock Units, Tax Withholding